Skip to main content
AVTX
NASDAQ Life Sciences

Avalo Therapeutics 以 737.5 万美元买下 1500 万美元里程碑付款，节省 760 万美元

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
7
Price
$14.42
Mkt Cap
$385.221M
52W Low
$3.39
52W High
$20.72
Market data snapshot near publication time

summarizeSummary

Avalo Therapeutics 已经签署协议，以 737.5 万美元买下之前披露的与其 2024 年 3 月收购 AlmataBio, Inc. 相关的 1500 万美元应付里程碑付款。该公司为一个可在 90 天内行使的选择权支付了 225 万美元，该选择权允许支付额外的 512.5 万美元现金或股票，或者两者的组合。这有效地将 1500 万美元的未来义务减少到 737.5 万美元，代表着净节省 762.5 万美元。这一财务举动是积极的发展，减少了一个临床阶段生物技术公司的重大未来负债，该公司在其最近的 10-K 中报告了扩大的净亏损和增加的现金支出。以股份支付的选择权也与公司现有的 7.5 亿美元普遍货架注册相一致。

在该公告发布时，AVTX的交易价格为$14.42，交易所为NASDAQ，所属行业为Life Sciences，市值约为$3.9亿。 52周交易区间为$3.39至$20.72。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed AVTX - Latest Insights

AVTX
Apr 28, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
8
Avalo Therapeutics Secures Option to Reduce $15M Contingent Milestone Payment to $7.375M
Sentiment: Positive
View Wiseek Article
AVTX
Apr 28, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Avalo Therapeutics Buys Out $15M Milestone for $7.375M, Saving $7.6M
Sentiment: Positive
View Wiseek Article
AVTX
Apr 23, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Avalo Therapeutics Q1'26 Revenue Estimate at $0, EPS Expected at ($1.18) Ahead of April 30 Release
Sentiment: Neutral
View Wiseek Article
AVTX
Apr 10, 2026, 4:01 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Avalo Therapeutics Seeks Shareholder Approval for ESPP Extension and Board Reduction
Sentiment: Negative
View Wiseek Article
AVTX
Mar 27, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Two Directors Depart Avalo Therapeutics Board Amidst Financial Challenges
Sentiment: Negative
View Wiseek Article
AVTX
Mar 23, 2026, 7:02 AM EDT
Filing Type: 10-K
Importance Score:
8
Avalo Therapeutics Reports Widened 2025 Net Loss, Increased Cash Burn, and Significant Dilution Potential Amidst Insider Selling Plans
Sentiment: Negative
View Wiseek Article
AVTX
Mar 23, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
7
Avalo Therapeutics Reports 2025 Financials, Extends Cash Runway into 2028, and Anticipates Key Phase 2 Data in Q2 2026
Sentiment: Positive
View Wiseek Article
AVTX
Mar 16, 2026, 4:39 PM EDT
Filing Type: 144
Importance Score:
7
Officer Files Intent to Sell $466K in Shares Following Option Exercise
Sentiment: Negative
View Wiseek Article
AVTX
Jan 12, 2026, 7:53 AM EST
Filing Type: 8-K
Importance Score:
8
Avalo Therapeutics Discloses $98M Cash, Extending Runway into 2028
Sentiment: Positive
View Wiseek Article
AVTX
Jan 08, 2026, 4:01 PM EST
Filing Type: S-3
Importance Score:
8
Avalo Therapeutics Files $750M Universal Shelf Registration, Signaling Substantial Future Dilution
Sentiment: Negative
View Wiseek Article